|
Colorectal Carcinoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<b/> BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity.
|
28576843 |
2017 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival.
|
30719102 |
2019 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<i>BRAF</i><sup>V600E</sup> mutations occur in ∼10% of colorectal cancer cases, are associated with poor survival, and have limited responses to BRAF/MEK inhibition with or without EGFR inhibition.
|
29483217 |
2018 |
|
Colorectal Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
(2016) show that in approximately 10% of BRAF-like colorectal cancer (CC) patients, Nup358/RanBP2 is critical for survival.
|
27203373 |
2016 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Colorectal cancer (CRC) mortality was not associated with the traditional, alternate, or serrated pathways, but was associated with a subset of pathway-unassigned tumors (MSS or MSI low, CIMP negative, BRAF mutation negative, and KRAS mutation positive) (n = 96 cases; relative risk = 1.76; 95% confidence interval, 1.07-2.89, compared with the traditional pathway).
|
23665275 |
2013 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency.
|
24066160 |
2013 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Colorectal cancers with BRAF D594G mutations exhibit similar clinicopathological features, microsatellite instability status, and prognosis as those with BRAF wild-type.
|
27404270 |
2016 |
|
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
CRC in KSA is usually diagnosed at advanced stages with metastases and KRAS/BRAF, and is associated with poor prognosis and short survival.
|
27915339 |
2017 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Colorectal cancer (CRC) growth and progression is frequently driven by RAS pathway activation through upstream growth factor receptor activation or through mutational activation of KRAS or BRAF.
|
29915291 |
2018 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Colorectal cancers (CRCs) initiate through distinct mutations, including in APC pathway components leading to tubular adenomas (TAs); in BRAF, with epigenetic silencing of CDX2, leading to serrated adenomas (SAs); and in the DNA mismatch repair machinery driving microsatellite instability (MSI).
|
30716341 |
2019 |
|
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Colorectal cancer (CRC) is categorized by alteration of vital pathways such as β-catenin (CTNNB1) mutations, WNT signaling activation, tumor protein 53 (TP53) inactivation, BRAF, Adenomatous polyposis coli (APC) inactivation, KRAS, dysregulation of epithelial to mesenchymal transition (EMT) genes, MYC amplification, etc.
|
31699039 |
2019 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF-V600E mutations were analysed by automatic sequencing in colorectal cancers from 206 sporadic cases with MSI-H and 111 HNPCC cases with known germline mutations in MLH1 and MSH2.
|
15342696 |
2004 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
B-RAF mutations, predominantly the specific V600E mutation and additional alterations in exons 11 and 15, were frequently detected in malignant melanomas, papillary thyroid tumors, and colorectal cancers with microsatellite instability (MSI).
|
16413100 |
2006 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation was detected in 20/72 (27.8%) CRC with defective MMR and in 3/40 (7.5%) proficient MMR controls (P = 0.011).
|
17065421 |
2006 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation testing has therefore been proposed as a means to more definitively identify and exclude sporadic MSI-H CRC cases from germline MMR gene testing.
|
17453358 |
2007 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF somatic mutations were reported with high frequency in sporadic colorectal cancers (CRCs) with microsatellite instability (MSI).
|
17566669 |
2007 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutation was analyzed in CRC patients with MMR deficiencies (microsatellite instability and/or lack of MLH1/MSH2 protein expression) in the EPICOLON population-based study.
|
18096441 |
2008 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation and CIMP+ are therefore likely to be involved in an alternate, albeit rare, pathway to APC inactivation during the development of CRC in younger patients.
|
18778891 |
2009 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E is the predominantly occurring mutation of the cytoplasmic kinase BRAF, and, in colorectal cancer, its determination provides a diagnostic exclusion criterion for hereditary nonpolyposis colorectal cancer.
|
19213871 |
2009 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation (V600E) is found in MSI colorectal cancers.
|
19289622 |
2009 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutation was found in 15.6% of colorectal cancers but at higher frequencies in cancers with proximal location, poor differentiation and microsatellite instability (MSI) (all p < 0.001).
|
20233436 |
2010 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) was associated with inferior overall survival in metastatic CRC (HR = 2.02; 95% CI 1.26-3.26), particularly evident in patients treated with chemotherapy, and is independent of MSI status.
|
20635392 |
2011 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations are specific for serrated adenocarcinoma and identify a subset of serrated adenocarcinomas with gene methylation and a tendency for MSI-H. A high frequency of KRAS mutations in serrated adenocarcinomas suggests that a significant proportion of KRAS-mutated CRCs originate from serrated precursors, thus challenging the traditional model of Vogelstein.
|
21457162 |
2011 |
|
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) ovarian cancers, 4/72 (5.5%) colorectal cancers, 1/355 (0.3%) lung cancers, 2/6 thyroid cancers and 1/2 choriocarcinomas.
|
22012135 |
2012 |